Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

DOJ Sues Regeneron for Allegedly Inflating Medicare Pricing for Eye Drug Eylea
BioSpace
Thu, 04/11/24 - 11:27 am
Tags:
DOJ, Regeneron, Medicare, Eylea, drug pricing, False Claims Act
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024
BioSpace
Wed, 03/27/24 - 11:06 am
Tags:
COPD, Sanofi, Regeneron, Verona Pharma, Dupixent, ensifentrine
FDA blocks approval of Regeneron's blood cancer drug over confirmatory trial enrollment
Fierce Biotech
Mon, 03/25/24 - 11:27 am
Tags:
Regeneron, FDA, odronextamab, clinical trials, blood cancers
After decades of waiting, late-stage therapies may penetrate the COPD market this year
Clinical Trials Arena
Sun, 03/24/24 - 10:31 pm
Tags:
COPD, drug development, Sanofi, Regeneron, Dupixent, Verona, ensifentrine
Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial
Fierce Biotech
Tue, 03/19/24 - 11:21 am
Tags:
Innovent, Regeneron, Bayer, anti-VEGF, neovascular age-related macular degeneration, IBI302, Eylea
US appeals court revives Regeneron's antitrust lawsuit against Novartis
Yahoo/Reuters
Mon, 03/18/24 - 05:09 pm
Tags:
Novartis, Regeneron, legal, Eylea, Lucentis, antitrust
Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial
Fierce Biotech
Mon, 03/11/24 - 11:52 am
Tags:
Incyte, clinical trials, prurigo nodularis, povorcitinib, Dupixent, Sanofi, Regeneron
Sanofi, Regeneron Secure FDA Priority Review for Dupixent in COPD
BioSpace
Fri, 02/23/24 - 10:43 am
Tags:
FDA, Sanofi, Regeneron, Dupixent, priority review, COPD
Regeneron Looks to Target Weight Loss Market with Muscle-Preserving Antibodies
BioSpace
Mon, 02/5/24 - 10:20 am
Tags:
Regeneron, obesity, muscle, drug development
2seventy bio to sell experimental cell therapies, names new CEO
Reuters
Tue, 01/30/24 - 10:23 am
Tags:
2seventy bio, Regeneron, Abecma, cell therapy
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
BioSpace
Fri, 01/26/24 - 11:19 am
Tags:
Regeneron, Sanofi, Dupixent, eosinic esophagitis, pediatric, FDA
Drugmakers explore muscle loss prevention when taking weight loss drugs
Beckers Hospital Review
Tue, 01/23/24 - 11:06 am
Tags:
weight loss, muscle, Ozempic, Wegovy, Eli Lilly, Regeneron
Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval
Clinical Trials Arena
Wed, 01/17/24 - 09:30 am
Tags:
CRISPR, gene editing, clinical trials, Casgevy, Vertex Pharmaceuticals, CRISPR Therapeutics, EdiGene, Shanghai Vitalgen BioPharma, Regeneron, Vor Biopharma
Regeneron hands off certain Libtayo rights in Europe to Medison Pharma
Fierce Pharma
Mon, 01/8/24 - 10:17 pm
Tags:
Regeneron, Libtayo, Europe, Madison Pharma
JPM24, Day 1: Regeneron's Eylea misses analyst estimates; Moderna touts $6.7B in '23 sales
Fierce Pharma
Mon, 01/8/24 - 11:45 am
Tags:
JPMHC 2024, Regeneron, Eylea, Eylea HD, Moderna Therapeutics
Regeneron Gains After Eye-Drug Patent Victory Over Viatris
Yahoo/Bloomberg
Sun, 12/31/23 - 11:46 am
Tags:
Regeneron, Eylea, Viatris, patents, legal
Dupixent for cancer? Researchers test blockbuster med as an immunotherapy-booster
Fierce Biotech
Thu, 12/7/23 - 11:13 pm
Tags:
Regeneron, Sanofi, Dupixent, cancer, lung cancer
Regeneron touts possible 'best-in-class' myeloma bispecific, but adverse events climb to 100%
Fierce Biotech
Thu, 12/7/23 - 11:52 am
Tags:
Regeneron, clinical trials, bispecific, Multiple Myeloma, patient deaths, linvoseltamab
Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Medical Marketing and Media
Tue, 11/28/23 - 10:27 am
Tags:
Sanofi, Regeneron, Dupixent, clinical trials, COPD
Regeneron stays out of ADC deal fray as in-house scientists tinker
Fierce Biotech
Wed, 11/15/23 - 11:08 am
Tags:
Regeneron, antibody-drug conjugate

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.